Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777162
Status:
UNKNOWN
Last Update Posted:
2021-03-04
First Post:
2021-02-25
Brief Title:
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Sponsor:
Organization:
Peking University